Search research articles
Contact Us
Filters
Showing results (651-660 of 792) with videos related to
Page
of 80
Sort By:
JTO Clinical and Research Reports
|
April 13, 2026
Treatment Patterns, Outcome, and Quality of Life of Patients With Extensive-Stage SCLC Receiving Third-Line Therapy-Data From the German CRISP Registry (AIO-TRK-0315): A Brief Report
Maximilian Rost, Rieke Fischer, Martin Reck, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 10, 2026
Phase 3 Study of Niraparib-Plus-Pembrolizumab as Maintenance Therapy for Advanced/Metastatic Non-Small Cell Lung Cancer (ZEAL-1L)
Suresh S Ramalingam, Vamsidhar Velcheti, Mehmet Altan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 28, 2010
Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop
Robert Pirker, Felix J F Herth, Keith M Kerr, et al.
The Lancet. Oncology
|
June 28, 2008
Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer
Michael Thomas, Christian Rübe, Petra Hoffknecht, et al.
Cancers
|
September 24, 2020
Mass Spectrometry Imaging for Reliable and Fast Classification of Non-Small Cell Lung Cancer Subtypes
Mark Kriegsmann, Christiane Zgorzelski, Rita Casadonte, et al.
Frontiers in Oncology
|
November 17, 2022
Serum cytokines predict efficacy and toxicity, but are not useful for disease monitoring in lung cancer treated with PD-(L)1 inhibitors
Hannah Schindler, Fabienne Lusky, Lea Daniello, et al.
International Journal of Cancer
|
January 25, 2018
EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK<sup>+</sup> non-small cell lung cancer
Petros Christopoulos, Volker Endris, Farastuk Bozorgmehr, et al.
Gesundheitswesen (Bundesverband Der Arzte Des Offentlichen Gesundheitsdienstes (Germany))
|
April 16, 2021
[Heidelberg Milestones Communication (HeiMeKOM) - Experiences, Best Practice Examples and Recommendations from the Final Symposium on January 30 and 31 in 2020]
Matthias Villalobos, Nicole Deis, Simone Wesselmann, et al.
Cancers
|
January 24, 2019
Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival
Petros Christopoulos, Steffen Dietz, Martina Kirchner, et al.
International Journal of Cancer
|
November 18, 2018
Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels
Volker Endris, Ivo Buchhalter, Michael Allgäuer, et al.
Page
of 80
Search research articles
Search
Showing results (651-660 of 792) with videos related to
Sort By:
Page
of 80
JTO Clinical and Research Reports
|
April 13, 2026
Treatment Patterns, Outcome, and Quality of Life of Patients With Extensive-Stage SCLC Receiving Third-Line Therapy-Data From the German CRISP Registry (AIO-TRK-0315): A Brief Report
Maximilian Rost, Rieke Fischer, Martin Reck, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 10, 2026
Phase 3 Study of Niraparib-Plus-Pembrolizumab as Maintenance Therapy for Advanced/Metastatic Non-Small Cell Lung Cancer (ZEAL-1L)
Suresh S Ramalingam, Vamsidhar Velcheti, Mehmet Altan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 28, 2010
Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop
Robert Pirker, Felix J F Herth, Keith M Kerr, et al.
The Lancet. Oncology
|
June 28, 2008
Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer
Michael Thomas, Christian Rübe, Petra Hoffknecht, et al.
Cancers
|
September 24, 2020
Mass Spectrometry Imaging for Reliable and Fast Classification of Non-Small Cell Lung Cancer Subtypes
Mark Kriegsmann, Christiane Zgorzelski, Rita Casadonte, et al.
Frontiers in Oncology
|
November 17, 2022
Serum cytokines predict efficacy and toxicity, but are not useful for disease monitoring in lung cancer treated with PD-(L)1 inhibitors
Hannah Schindler, Fabienne Lusky, Lea Daniello, et al.
International Journal of Cancer
|
January 25, 2018
EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK<sup>+</sup> non-small cell lung cancer
Petros Christopoulos, Volker Endris, Farastuk Bozorgmehr, et al.
Gesundheitswesen (Bundesverband Der Arzte Des Offentlichen Gesundheitsdienstes (Germany))
|
April 16, 2021
[Heidelberg Milestones Communication (HeiMeKOM) - Experiences, Best Practice Examples and Recommendations from the Final Symposium on January 30 and 31 in 2020]
Matthias Villalobos, Nicole Deis, Simone Wesselmann, et al.
Cancers
|
January 24, 2019
Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival
Petros Christopoulos, Steffen Dietz, Martina Kirchner, et al.
International Journal of Cancer
|
November 18, 2018
Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels
Volker Endris, Ivo Buchhalter, Michael Allgäuer, et al.
Page
of 80